Past Tuesday Talks — A Father Who is Changing the Landscape for Type 1 Diabetes Patients
Tuesday, August 22, 2023
Presented by Seema Kumar, CEO, Cure
This week on Tuesday Talks, Cure CEO, Seema Kumar sits down with Dr. Ed Damiano, Founder and Executive Chair of medical device company Beta Bionics which was born out his young son’s diagnosis of Type 1 diabetes. Watch to find out how Dr. Damiano and his team are changing the landscape for patients living with Type 1 diabetes with their recent FDA cleared iLet Bionic Pancreas that was 20 years in the making.
Topic: A fireside chat Dr. Ed Damiano, on new treatments for Type 1 diabetes.
Speakers: Dr. Ed Damiano, Founder and Executive Chair of medical device company Beta Bionics. Hosted by Seema Kumar, CEO of Cure
Featured Speakers
About Dr Ed Damiano
Dr Damiano is a co-founder of Beta Bionics. Ever since his son developed type 1 diabetes at 11 months of age, Dr Damiano has been committed to building a bihormonal bionic pancreas. Dr Damiano has been a Professor of Biomedical Engineering at Boston University since 2004. He was an Assistant Professor of Mechanical Engineering at the University of Illinois prior to that. Ed received a Ph.D. in Applied Mechanics and a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.S. in Mechanical Engineering from Washington University in St. Louis.
About Seema Kumar
Seema joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J’s Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company’s external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.
